ClinicalTrials.gg
RecruitingNCT07248540IVMAGUpdated Nov 25, 2025

IV Magnesium in the Treatment of Acute Dysmenorrhea

An interventional study of Magnesium Sulfate (2 Ampoules) and Dexketoprofen in Dysmenorrhea, sponsored by Havva Betül Bacak. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Havva Betül Bacak · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Jul 2025, registered Nov 2025).
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Dysmenorrhea with a site in Turkey — 19 open to participants now, 23 under way, none of them phase 3. Dysmenorrhea · Turkey.

Planned enrollment
36th of 72
60 · median 60
Started
2025
with 12 others
No phase
70 of 81
16 open now
Primary completion
2026-01
later than 13 of 22 live
Registered
64th of 81
by date

Among the 81 studies in Dysmenorrhea with a site in Turkey, this one is the 36th largest by planned enrollment of the 72 interventional ones that give a count, is one of 13 that started in 2025, is one of 70 with no phase, reaches primary completion later than 13 of the 22 other live ones, and was the 64th registered.

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.

Browse Dysmenorrhea studies →

Open to participants now

19 of the 81 studies in Dysmenorrhea with a site in Turkey are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 11 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Dysmenorrhea with a site in Turkey, or all of them as a file.
02

Study summary

This prospective, randomized, double-blind clinical trial aims to evaluate the analgesic efficacy of intravenous magnesium sulfate in women presenting to the emergency department with acute dysmenorrhea. Participants will be randomized into two groups receiving either 2 ampoules of magnesium sulfate or intravenous dexketoprofen. Pain levels will be assessed using the Visual Analog Scale (VAS) before and after treatment.

Read the detailed description

This prospective, randomized, double-blind clinical trial is designed to evaluate the analgesic effectiveness of intravenous magnesium sulfate in women aged 18 to 35 years presenting to the emergency department with acute dysmenorrhea. Participants will be randomly assigned to one of two treatment groups: 2 ampoules of magnesium sulfate or intravenous dexketoprofen.

All medications will be diluted in 100 ml of normal saline and administered intravenously over 15 minutes. Pain intensity will be assessed using the Visual Analog Scale (VAS) before treatment and 1 hour after administration. Secondary outcomes include patient satisfaction, vital sign changes, and adverse effects.

The study aims to compare the analgesic efficacy and safety profile of intravenous magnesium sulfate with that of a standard nonsteroidal anti-inflammatory drug (dexketoprofen) in the management of acute dysmenorrhea.

03

Conditions studied

  • Dysmenorrhea

Browse trials for

Keywords

  • Dysmenorrhea
  • Magnesium Therapy
  • Pain Management
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Female patients aged 18 to 35 years

Presenting to the obstetrics and gynecology emergency department with a diagnosis of primary dysmenorrhea

Having regular menstrual cycles within the last 6 months

Having a Visual Analog Scale (VAS) pain score of ≥6 at emergency admission

Providing written for participation in the study

Exclusion criteria

Exclusion Criteria:

Patients with secondary dysmenorrhea or underlying gynecological pathology

Pregnancy or breastfeeding

Use of analgesics or muscle relaxants within the last 3 days

Known allergy to magnesium sulfate or dexketoprofen trometamol

History of renal failure, cardiac arrhythmia, or serious systemic disease

Inability to assess pain due to mental disability or communication disorder

Failure to provide for participation in the study

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Magnesium Sulfate 2 Ampoules

    Participants receive 2 ampoules (8 ml total) of intravenous magnesium sulfate diluted in 100 ml normal saline, administered over 15 minutes.

    Drug: Magnesium Sulfate (2 Ampoules)

  • Active comparator
    Intravenous Dexketoprofen

    Participants receive 50 mg of intravenous dexketoprofen diluted in 100 ml normal saline, administered over 15 minutes.

    Drug: Dexketoprofen

Interventions

  • Intravenous administration of 2 ampoules (8 ml total) of magnesium sulfate diluted in 100 ml normal saline, infused over 15 minutes.

  • Intravenous administration of 50 mg dexketoprofen diluted in 100 ml normal saline, infused over 15 minutes.

06

What researchers measure

Primary outcomes

  1. Change in pain intensity measured by Visual Analog Scale (VAS)

    Pain severity will be assessed using the 0-10 Visual Analog Scale (VAS) before treatment and 1 hour post-treatment. The study will evaluate and compare the analgesic effect of two different doses of intravenous magnesium sulfate (2 ampoules vs. 3 ampoules) and compare both to intravenous dexketoprofen in women presenting with acute dysmenorrhea.

    Time frame: Baseline and 1 hour after intravenous treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jan 2026, 6 months after the start.

Of 178 non-industry interventional studies with no phase under Dysmenorrhea, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 6 months is below that.

Counting every sponsor, half of 188 studies reached it within 8 months; a quarter within 3 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 25, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Jan 1, 2026
CompletionEst.
Jan 1, 2026
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07248540
Lead sponsor
Havva Betül Bacak
Responsible party
Havva Betül Bacak (md, Gaziosmanpasa Research and Education Hospital) — Sponsor-investigator
First posted
Nov 25, 2025
Start date
Jul 1, 2025
Primary completion
Jan 1, 2026 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Nov 25, 2025

Study contacts

ecenur çelikoğlu, md
Contact
ecenurcelikoglu14@gmail.com
+90 538 54 92 848
yağmur acıyiyen, md
Contact
yagmuraciyiyen95@gmail.com
+905425669593
havva betül bacak, md
principal investigator · SBÜ Gaziosmanpaşa Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Magnesium Sulfate

Start the discussion